Certara, Inc. (NASDAQ:CERT) Shares Acquired by Blue Trust Inc.

Blue Trust Inc. grew its stake in Certara, Inc. (NASDAQ:CERT) by 112.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,925 shares of the company’s stock after buying an additional 2,076 shares during the quarter. Blue Trust Inc.’s holdings in Certara were worth $46,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Innealta Capital LLC acquired a new position in Certara in the 2nd quarter worth about $36,000. Intech Investment Management LLC acquired a new position in Certara in the 2nd quarter worth about $152,000. Algert Global LLC acquired a new position in Certara in the 2nd quarter worth about $156,000. MQS Management LLC acquired a new position in Certara in the 2nd quarter worth about $162,000. Finally, SG Americas Securities LLC acquired a new position in Certara in the 2nd quarter worth about $226,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Insider Activity

In related news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.39% of the company’s stock.

Wall Street Analysts Forecast Growth

CERT has been the subject of a number of analyst reports. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a report on Friday, September 27th. Barclays cut their price objective on Certara from $16.00 to $14.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 15th. JMP Securities reiterated a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. KeyCorp cut their price objective on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Robert W. Baird cut their price objective on Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $17.08.

Certara Price Performance

CERT stock opened at $10.25 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. The business has a 50 day simple moving average of $11.22 and a 200-day simple moving average of $13.90. The firm has a market capitalization of $1.65 billion, a PE ratio of -20.50, a price-to-earnings-growth ratio of 4.91 and a beta of 1.49. Certara, Inc. has a 1 year low of $9.99 and a 1 year high of $19.87.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $93.31 million during the quarter, compared to analysts’ expectations of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. Certara’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter last year, the company earned $0.10 earnings per share. Equities research analysts anticipate that Certara, Inc. will post 0.27 earnings per share for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.